Julie is a dedicated resource for summer associates and associates who want to sharpen their legal writing skills. She works one-on-one with lawyers and teaches workshops that address common writing challenges. In Chambers Associate, our associates called Julie "an invaluable asset to the firm."
Women in Law Empowerment Forum awarded Schiff Hardin its 2015 Gold Standard in Recognition of Integration of Women in the Firm for the 3rd straight year. Schiff Hardin was one of only eight firms in the nation to earn a perfect score.
Co-leader of Schiff Hardin’s Intellectual Property Group, Imron T. Aly also serves as co-chair of the firm's Pharmaceuticals and Biologics Patent Litigation Team. He focuses his practice in patent infringement and trade secret misappropriation litigation. He has litigated and managed patent infringement and trade secret matters for pharmaceuticals, medical implants and devices, DNA arrays, mechanical production assemblies, computer business methods and financial trading systems.
Prior to joining Schiff Hardin, Imron was an intellectual property partner in the Chicago office of an international law firm.
Imron's representative matters prior to joining Schiff Hardin include:
Richard Linn American Inn of Court
Guest Lecturer, Patent Litigation, University of Michigan (2011, 2013)
Schiff Hardin LLP has been recognized as one of the top law firms defending Abbreviated New Drug Application (ANDA) litigation in the 2017 Hatch-Waxman/ANDA Litigation Report compiled by legal data analytics firm Lex Machina.
Schiff Hardin LLP today announced the addition of Kevin M. Nelson as a partner in its rapidly growing Intellectual Property Group.
The Supreme Court recently agreed to hear a challenge to the current interpretation of the venue statute in patent infringement cases.
Thirty-nine Schiff Hardin attorneys have been selected for inclusion on the 2017 Illinois Super Lawyers and Rising Stars lists.
Schiff Hardin is pleased to announce that Benchmark Litigation’s ninth edition honored the firm as a “Recommended Firm” in Illinois.
Schiff Hardin’s pharma and life sciences patent litigation team, lead by partner Imron T. Aly, recently secured a preliminary injunction in federal court.
Supreme Court Holds that Decision to Institute IPR is Non-appealable and PTAB’s “Broadest Reasonable Construction” Standard for Claim Construction is Lawful
Imron has represented indigent clients in trademark and copyright, contract dispute, landlord-tenant, prisoner rights and elder abuse matters.
Metropolitan Tenants Organization
Former Board Member
Managing Intellectual Property
BTI Power Ranking
Managing Intellectual Property Magazine
Globe Business Media Group's The World’s Leading Patent Practitioners (2014, 2015)
Chambers USA: America’s Leading Lawyers for Business (2014)
Euromoney's Benchmark Litigation (2013, 2014)
Shortly after approving the first biosimilar under the abbreviated approval pathway created by the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), the FDA has recently issued 3 final guidances regarding biosimilars. Biological products, or “biologics,” are pharmaceutical products created from biological sources. Unlike chemically synthesized pharmaceuticals, biologics are isolated from natural sources, and...… Continue Reading
Schiff Hardin’s pharma and life sciences patent litigation team, led by partner Imron T. Aly, recently secured a preliminary injunction in federal court. Representing generic drug manufacturer Fresenius Kabi USA, LLC, our team convinced the judge to bar our client’s competitor from launching a generic version of levothyroxine, our client’s patented treatment formulation.